Objectives: Hospital readmission has been an important issue in patients with chronic obstructive pulmonary disease (COPD), as it reflects exacerbation of the disease and quality of medical care, and incurs high medical expenditures. This study aimed to examine pattern and economic burden of readmission, and identify factors associated with risk of readmission in patients hospitalized for COPD in Taiwan. MethOds: The National Health Insurance claims database of a representative sample (two million subjects) of Taiwanese population in 2005 was adopted for this study. Adult individuals who were discharged from acute hospitals for COPD in 2005 were selected and their readmission pattern one-year after discharge were examined. Cox proportional hazards regression models were adopted to identify factors associated with risk of readmission. Results: The majority of the subjects was male and aged older than 65 years old. The 30-day, 3-month and one-year all-cause readmission rates were 28%, 46%, and 69%, respectively. The 30-day, 3-month and one-year COPD-specific readmission rates were 10%, 17%, and 31%, respectively. Approximately one-fourth of the subjects were readmitted more than twice during the follow-up. COPD, pneumonia, and respiratory failure/insufficiency/arrest were the top three most frequent causes for readmission during 30 days, 3 months, or one year after discharge. In the one-yar follow-up, hospital readmission accounted for 73% of total healthcare expenditures. Gender, previous hospitalization history, comorbidities, and length of stay and hospital accreditation level of the index hospitalization were associated with risk of allcause readmission. Gender, previous hospitalization history, and length of stay and hospital accreditation level of the index hospitalization were associated with risk of COPD-specific readmission. cOnclusiOns: This study identified patterns and causes of short-term and long-term readmission, and factors associated with risk of readmission in patients hospitalized for COPD. The information is of importance for planning interventions to reduce hospital readmission rate.
was based on the average monthly salary in the UK. A conservative assumption was made about the increased risk of a productive day being lost -associated with level of patient satisfaction to their treatment -by calculating an approximate number of unscheduled hospitalisations that users of a new inhaler would experience in the previous 12 months relative to Spiriva® HandiHaler®. Patient satisfaction with their inhaler was based on inhaler features that relate to ease of use and ergonomics and compared Spiriva® HandiHaler® to an improved inhaler. Results: The frequency of unscheduled hospitalisations for the new inhaler and Spiriva® HandiHaler® users were calculated at 0.34 and 0.38, resulting in 68 and 76 productive days lost annually, respectively. The total annual societal cost per patient was € 9,851 with the new inhaler and € 10,891 with Spiriva® HandiHaler®. The new inhaler costs € 1,040 less per annum than Spiriva® Handihaler®. ConClusions: New inhalers with improved features have the potential to offer substantial societal cost savings in COPD compared with Spiriva® Handihaler®.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations –citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.